<DOC>
	<DOCNO>NCT00544167</DOCNO>
	<brief_summary>Sorafenib look number solid tumor setting include breast cancer . This trial design pilot study assess safety tolerability novel oral agent combination standard chemotherapy treatment early stage node positive otherwise high-risk breast cancer . If prove tolerable regimen patient , would provide rationale study large randomized fashion .</brief_summary>
	<brief_title>Adjuvant Doxorubicin/Cyclophosphamide Paclitaxel Plus Sorafenib Breast Cancer</brief_title>
	<detailed_description>Primary Objectives The primary objective ass safety tolerability doxorubicin / cyclophosphamide follow paclitaxel combination sorafenib patient early stage node positive otherwise high-risk breast cancer . Secondary Objectives The secondary objective assess activity form recurrence-free-interval , distant recurrence-free interval , overall survival pilot study doxorubicin / cyclophosphamide follow paclitaxel combination sorafenib patient early stage node positive otherwise high-risk breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histologicallyconfirmed breast cancer interval definitive surgery include axillary lymph node involvement assessment initiation study treatment less equal 84 day . Definitive surgery either mastectomy axillary node involvement assessment , breast conserving surgery axillary node assessment . Margins resect specimen must free invasive disease and/or ductal carcinoma situ ( DCIS ) . Stage I , II , IIIA , IIIC ( T13 , N3a ) . Patients must either lymph node positive highrisk node negative . Age &gt; 18 year . ECOG performance status 0 1 . Normal cardiac function must confirm leave ventricular ejection fraction ( LVEF ) Echocardiography MUGA scan electrocardiogram ( ECG ) within 35 day prior initiation study treatment . Patients must adequate bone marrow function Patients must normal liver function ( Serum creatinine &lt; = 2mg/dl INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor . Prior systemic anticancer therapy breast cancer ( immunotherapy , chemotherapy , hormonal therapy ) . Patients HER2 positive breast cancer determine FISH IHC3+ stand ineligible trial . Prior anthracycline taxane therapy . Prior radiation therapy breast cancer . Bilateral invasive disease . Preexisting motor sensory neurotoxicity severity ≥ 2 NCI CTCAE v 3.0 criterion . Cardiac disease include : myocardial infarction ; angina , congestive heart failure , arrhythmia ; valvular heart disease ; cardiomegaly chest image ventricular hypertrophy ECG unless LVEF within normal range institution ; patient poorly control hypertension ( define systolic blood pressure &gt; 150 /or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) ; patient receive medication angina , arrhythmia , congestive heart failure . Current therapy raloxifene , tamoxifen selective estrogen receptor modulator Concurrent treatment ovarian hormonal replacement therapy . History prior malignancy within 5 year exception skin cancer cervical carcinoma situ . Women pregnant ( positive pregnancy test ) breast feeding . Subjects childbearing potential must use effective birth control measure treatment . Treatment nonapproved investigational drug within 30 day day 1 trial treatment . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Thrombotic embolic event stroke transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event ≥ NCI CTCAE v3.0 Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event ≥ NCI CTCAE v3.0 Grade 3 within 4 week first dose study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Early Stage</keyword>
	<keyword>High Risk</keyword>
	<keyword>Node Positive</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Sorafenib</keyword>
</DOC>